Log in or Sign up for Free to view tailored content for your specialty!
Neurosciences News
Two classes of molecules in uveal melanoma suggest different treatments
NEW YORK — The identification of two distinct forms of molecules in uveal melanoma may lead to significant advances in the treatment of the disease, said one researcher speaking here.
Etanercept suppressed signs of Graves’ ophthalmopathy in trial
Etanercept, a drug used in the treatment of rheumatoid arthritis, may be beneficial in the treatment of Graves’ ophthalmopathy, a study suggests.
Log in or Sign up for Free to view tailored content for your specialty!
Retinal pigment epithelial alterations leading factor in tumor growth
Patients with ocular tumors tend to have poor visual acuity, and patients with decalcified subfoveal choroidal osteoma have a particularly poor visual prognosis, according to results of a long-term study.
Etanercept, isoniazid may lead to optic neuritis
Two common drugs for the treatment of rheumatoid arthritis and tuberculosis may cause patients to develop optic neuritis, according to a case study. Discontinuation of the pharmaceuticals should help resolve the neuritis, the study authors said.
RPE cell implants show promise as Parkinson’s disease therapy
Implanting retinal pigment epithelial cells into the brain may be a beneficial treatment for Parkinson’s disease, a pilot trial in humans suggests.
Proton therapy planning device for ocular cancer given 501(k) clearance
PALO ALTO, Calif. — A calculation module for planning radiation treatments for eye cancers has been granted Food and Drug Administration 510(k) clearance, according to the device’s maker. The new proton therapy eye dose calculation module will be part of the Varian Eclipse treatment planning system, Varian said in a press release.
Treatment options promising for optic nerve sheath meningioma
CHICAGO — While there is still no ideal treatment for optic nerve sheath meningioma, recent advances in radiation therapy have provided promising outcomes that bode well for management of these tumors in the future, according to Neil R. Miller, MD.
Look for commonly missed etiologies to explain visual loss with normal fundus
CHICAGO — When confronted with unexplained visual loss in patients with a normal fundus, neuro-ophthalmologists should first seek to identify the anatomic location of the pathology and then, if no pathology is found, seek to prove that the visual loss is nonorganic, according to a presenter here.
Vision loss in cancer patients deserves special consideration
CHICAGO — General ophthalmologists and neuro-ophthalmologists alike must be aware that a history of cancer is an important factor in diagnosing vision loss in their patients, said Nicholas J. Volpe, MD. In patients with such a history, complications of cancer must be considered in the differential diagnosis to ensure proper management, he said.
Retinopathy a predictor of stroke in nondiabetics, Australian study finds
Retinopathy signs predict stroke or stroke-related death independent of traditional risk factors for stroke, an Australian population-based study found.